This is in agreement with the losartan-mediated reduction in cardiac fibrosis via TGF-β anatagonism that has been reported in several other models of cardiomyopathy [18], [19], [20], [21], [22]. The gene discussed is TGFB1; the disease is cardiomyopathy.